Drug Profile


Alternative Names: Lead Candida-Staph vaccine - NovaDigm Therapeutics; NDV-3; NDV-3A; Prophylactic candidiasis/MRSA vaccine - NovaDigm Therapeutics; Recombinant protein vaccine (NDV-3) against S.aureus and Candida - NovaDigm Therapeutics

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator LA BioMed; NovaDigm Therapeutics
  • Developer National Institute of Allergy and Infectious Diseases; NovaDigm Therapeutics
  • Class Antibacterials; Antifungals; Bacterial vaccines; Fungal vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Candidiasis; Staphylococcal infections
  • Phase I/II Vulvovaginal candidiasis
  • No development reported Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 01 Nov 2016 Phase-II clinical trials in Candidiasis (Prevention, in patients with autosomal dominant hyper-IgE syndrome) in USA (IM) (NCT02996448)
  • 01 Nov 2016 Phase-II clinical trials in Staphylococcal infections (Prevention, in patients with autosomal dominant hyper-IgE syndrome) in USA (IM) (NCT02996448)
  • 15 Aug 2016 Efficacy and adverse events data from a phase IIa trial in Vulvovaginal candidiasis (Prevention, Recurrent) released by NovaDigm Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top